Predict your next investment

Venture Capital
sbi-ji.co.il

See what CB Insights has to offer

Investments

8

Portfolio Exits

3

Funds

1

About SBI JI Innovation Fund

SBI JI Innovation Fund is a biopharma focused venture capital firm. SBI JI Innovation Fund was formed as a partnership between SBI Holdings of Japan and Vertex.

SBI JI Innovation Fund Headquarter Location

Akerstein Towers B, 3rd Floor 11 HaMenofim St.

Herzliya,

Israel

+972-7-250-0610

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest SBI JI Innovation Fund News

Biosight Secures $19M in Series C Funding

Mar 12, 2020

Biosight Ltd. , a Airport City, Israel-based pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, raised $19M in Series C financing. The round was led by Israel Biotech Fund (IBF) with participation from SBI JI Innovation Fund, Arkin Bio Ventures, and additional new and existing investors. The company intends to use the funds to advance the clinical development of its lead asset BST-236 (aspacytarabine), currently being investigated in a Phase 2b study as a single-agent, first-line treatment of acute myeloid leukemia (AML). Led by Dr. Ruth Ben Yakar, Chief Executive Officer, Biosight is a private clinical-stage biotech company, developing innovative therapeutics for hematological malignancies and disorders, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The BST-236 (aspacytarabine) is a novel proprietary anti-metabolite composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. BST-236 is designed to enable high-dose therapy with lower systemic exposure to free cytarabine and relative sparing of normal tissues. As such, BST-236 may serve as a superior therapy for AML and other hematological malignancies and disorders, including for older adults who are unfit for intensive therapy. BST-236 was granted Orphan Drug Designation from the FDA, which entitles Biosight to seven years of market exclusivity upon BST-236 marketing approval for the treatment of AML. FinSMEs

SBI JI Innovation Fund Investments

8 Investments

SBI JI Innovation Fund has made 8 investments. Their latest investment was in BioSight as part of their Series C on March 3, 2020.

CBI Logo

SBI JI Innovation Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/11/2020

Series C

BioSight

$19M

Yes

4

10/2/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

5/28/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

2/20/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

1/8/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/11/2020

10/2/2019

5/28/2019

2/20/2019

1/8/2019

Round

Series C

Series B

Series B

Series B

Series B

Company

BioSight

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$19M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

10

10

10

10

SBI JI Innovation Fund Portfolio Exits

3 Portfolio Exits

SBI JI Innovation Fund has 3 portfolio exits. Their latest portfolio exit was Ayala Pharmaceuticals on May 08, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/8/2020

IPO

$99M

Public

5

4/29/2020

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

10/28/2019

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/8/2020

4/29/2020

10/28/2019

Exit

IPO

Reverse Merger

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

5

10

10

SBI JI Innovation Fund Fund History

1 Fund History

SBI JI Innovation Fund has 1 fund, including SBI JI Innovation Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

SBI JI Innovation Fund

Multi-Stage Venture Capital

Open

1

Closing Date

Fund

SBI JI Innovation Fund

Fund Type

Multi-Stage Venture Capital

Status

Open

Amount

Sources

1

SBI JI Innovation Fund Team

3 Team Members

SBI JI Innovation Fund has 3 team members, including current Chief Executive Officer, Larry Montgomery.

Name

Work History

Title

Status

Larry Montgomery

Chief Executive Officer

Current

David Ben Ami

General Partner

Current

David Heller

General Partner

Current

Name

Larry Montgomery

David Ben Ami

David Heller

Work History

Title

Chief Executive Officer

General Partner

General Partner

Status

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.